Sai Parenteral’s IPO Details
| IPO Open Date | March 24, 2026 |
| IPO Close Date | March 27, 2026 |
| Face Value | â‚ą5 Per Equity Share |
| IPO Price Band | â‚ą372 to â‚ą392 Per Share |
| Issue Size | Approx â‚ą409 Crores |
| Fresh Issue | Approx â‚ą285 Crores |
| Offer for Sale: | Approx 35,00,000 Equity Shares |
| Issue Type | Book build Issue |
| IPO Listing | BSE, NSE |
| DRHP Draft Prospectus |  |
| RHP Draft Prospectus | |
Sai Parenteral’s IPO Review & Key Points
- Review: Neutral
Sai Parenteral’s IPO Market Lot
The Sai Parenteral’s IPO minimum market lot is 38 shares with â‚ą14,896 application amount. The retail investors can apply up-to 13 lots with 494 shares of â‚ą1,93,648 amount.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 1 | 38 | â‚ą14,896 |
| Retail Maximum | 13 | 494 | â‚ą1,93,648 |
| S-HNI Minimum | 14 | 532 | â‚ą2,08,544 |
| S-HNI Maximum | 67 | 2,546 | â‚ą9,98,032 |
| B-HNI Minimum | 68 | 2,584 | â‚ą10,12,928 |
IPO Reservation
| Investor Category | Share Offered | Shares (%) |
| Anchor Investor | 31,28,485 Shares | 30% |
| QIB (Ex. Anchor) | 20,85,659 Shares | 20% |
| NII Shares Offered | 15,64,243 Shares | 15% |
| Retail Shares Offered | 36,49,901 Shares | 35% |
Sai Parenteral’s IPO Anchor Investors
| Anchor Bidding Date | March 23, 2026 |
| Anchor Investors List | |
| Shares Offered | 31,28,485 Shares |
| Anchor Size | 122.64 Cr. |
| lock-in period end date 50% shares (30 Days) | April 29, 2026 |
| lock-in period end date 50% shares (90 Days) | June 28, 2026 |
Sai Parenteral’s IPO Dates
The Sai Parenteral’s IPO date is March 24 and the close date is March 27. The Sai Parenteral’s IPO allotment will be finalized on March 30 and the IPO listing on April 2.
| IPO Open Date: | March 24, 2026 |
| IPO Close Date: | March 27, 2026 |
| Basis of Allotment: | March 30, 2026 |
| Refunds: | April 1, 2026 |
| Credit to Demat Account: | April 1, 2026 |
| IPO Listing Date: | April 2, 2026 |
| IPO Bidding Cut-off Time: | March 27, 2026 |
Promoters and Holding Pattern
The promoters of the company are Anil Kumar Karusala, Vijitha Gorrepati and Karusala Aruna.
| Particular | Shares | % Share |
| Promoter Holding Pre Issue | 3,69,08,823 | 61.23% |
| Promoter Holding Post Issue | 4,41,79,231 | -% |
Objects of the Issue & Utilisation of Proceeds
| Purpose | Crores |
| Capacity expansion and upgradation of manufacturing facilities | â‚ą110.80 |
| Establishment of a new R&D Centre; | â‚ą18.02 |
| Repayment / prepayment of certain outstanding borrowings | â‚ą20.00 |
| Working capital requirements | â‚ą33.00 |
| Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia); and | â‚ą36.00 |
| General corporate purposes | â‚ą- |
About Sai Parenteral’s IPO
Sai Parenteral’s Ltd., founded in 2001, is one of the leading pharmaceutical companies focused on R&D and manufacturing of pharmaceutical products. The firm operates in 2 main business areas: makes and sells its own branded medicines, and also manufactures medicines for other companies internationally. Its product offerings include a wide range of medicines for various health conditions, like cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals, and supplements (VMS), analgesics, and dermatology.
Its medicines are available in various forms like tablets, injections, and syrups. Sai Parenteral’s major clients are government agencies, pharmaceutical companies, public and private hospitals, and large distributors in India. The firm operates 5 manufacturing facilities in India, mainly located in Hyderabad, known for developing medicines with international quality certifications.
Sai Parenteral’s IPO Company Financial Report
Amount â‚ą in Crores
| Period Ended | Revenue | Expense | PAT | Assets |
| 2023 | â‚ą97.03 | â‚ą89.78 | â‚ą4.38 | â‚ą133.96 |
| 2024 | â‚ą155.18 | â‚ą142.63 | â‚ą8.42 | â‚ą268.10 |
| 2025 | â‚ą163.74 | â‚ą143.84 | â‚ą14.43 | â‚ą272.39 |
| Sep 2025 | â‚ą89.43 | â‚ą78.27 | â‚ą7.76 | â‚ą376.24 |
Sai Parenteral’s IPO Valuation – FY2025
Check Sai Parenteral’s IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| KPI | Values |
| ROE: | 15.09% |
| ROCE: | 28.92% |
| EBITDA Margin: | 24.18% |
| PAT Margin: | 8.88% |
| Debt to equity ratio: | – |
| Earning Per Share (EPS): | â‚ą5.43 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 15.09% |
| Net Asset Value (NAV): | â‚ą35.98 |
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Sai Life Sciences Limited | 8.83 | 107.70 | 7.99% | 102.12 | 1,694.57 Cr. |
| Innova Captab Limited | 22.41 | 32.45 | 13.37% | 167.66 | 1,243.68 Cr. |
| Senores Pharmaceuticals Limited | 16.12 | 64.30 | 7.18% | 176.37 | 398.25 Cr. |
| Gland Pharma Limited | 42.40 | 44.71 | 7.63% | 555.41 | 5,616.50 Cr. |
| Industry Average | – | 62.29 | – | – | – Cr. |
IPO Lead Managers aka Merchant Bankers
- Arihant Capital Markets Ltd.
Company Address
Sai Parenteral’s Ltd.
Plot No 39
5th floor, Lavanya Arcade, Jayabheri Enclave
Gachibowli, K.V.Rangareddy, Seri Lingampally
Hyderabad, Telangana, 500032
Phone: +91 79979 91301
Email: cs@saiparenterals.com
Website: https://www.saiparenterals.com/
IPO Registrar
Bigshare Services Pvt. Ltd.
Phone: +91-22-6263 8200
Email: ipo@bigshareonline.com
Website: https://ipo.bigshareonline.com/IPO_Status.html
Sai Parenteral’s IPO FAQs
What is Sai Parenteral’s IPO?
When Sai Parenteral’s IPO will open for subscription?
What is Sai Parenteral’s IPO Investors Portion?
How to Apply the Sai Parenteral’s IPO?
What is Sai Parenteral’s IPO Issue Size?
What is Sai Parenteral’s IPO Price Band?
What is Sai Parenteral’s IPO Lot Size?
What is the Sai Parenteral’s IPO Allotment Date?
What is the Sai Parenteral’s IPO Listing Date?
Note: The Sai Parenteral’s IPO price band and date are officially announced. The (Sai Parenteral’s IPO grey market premium) will be added to the IPO GMP page as it will start).
